Product Description
first C-nucleoside HCV polymerase inhibitor for antiviral response in HCV infected patients (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23547794/)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hepatitis C, Chronic|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GS-US-119-0101 | P1 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2011-10-01 |